Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Refractory Solid Tumors 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1

Interventions

Fulvestrant 26Letrozole 25Specimen Handling 19ribociclib 18Capecitabine 16pembrolizumab 15palbociclib 13Trastuzumab 13Paclitaxel 13abemaciclib 12Tamoxifen 12Anastrozole 12exemestane 11Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 10Carboplatin 10Biopsy 9pertuzumab 8Goserelin 8inavolisib 6Standard of Care 6Cyclophosphamide 6olaparib 5giredestrant 5elacestrant 5Taxes 5Radiotherapy 5Radiation 5130-nm albumin-bound paclitaxel 5pyrotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Breast Neoplasms × eribulin × 30 days × Clear all
NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06875128 2026-06-01

DELUMA

Delcath Systems Inc.

Phase 2 Recruiting
90 enrolled
Breast

Breast Neoplasms

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3 Recruiting
376 enrolled
Breast

Breast Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

BioNTech SE

Phase 3 Recruiting
558 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡